Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

被引：0
|
作者：
Yuya Seko
Yoshio Sumida
Kazuyo Sasaki
Yoshito Itoh
Hiroaki Iijima
Toshio Hashimoto
Shinichi Ishii
Nobuya Inagaki
机构：
[1] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology
[2] Mitsubishi Tanabe Pharma Corporation,Department of Diabetes, Endocrinology and Nutrition
[3] Mitsubishi Tanabe Pharma Corporation,undefined
[4] Kyoto University Graduate School of Medicine,undefined
来源：
Journal of Gastroenterology | 2018年 / 53卷
关键词：
Alanine aminotransferase; Canagliflozin; Hepatic function; Japan; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：140 / 151
页数：11
相关论文
共 50 条
  • [1] Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
    Seko, Yuya
    Sumida, Yoshio
    Sasaki, Kazuyo
    Itoh, Yoshito
    Iijima, Hiroaki
    Hashimoto, Toshio
    Ishii, Shinichi
    Inagaki, Nobuya
    JOURNAL OF GASTROENTEROLOGY, 2018, 53 (01) : 140 - 151
  • [2] Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials
    Seko, Yuya
    Sumida, Yoshio
    Sasaki, Kazuyo
    Itoh, Yoshito
    Iijima, Hiroaki
    Hashimoto, Toshio
    Ishii, Shinichi
    Inagaki, Nobuya
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E797 - E798
  • [3] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [4] Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
    Nigro, Stefanie C.
    Riche, Daniel M.
    Pheng, Michelle
    Baker, William L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1301 - 1311
  • [5] Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
    Yshai Yavin
    Traci A. Mansfield
    Agata Ptaszynska
    Kristina Johnsson
    Shamik Parikh
    Eva Johnsson
    Diabetes Therapy, 2016, 7 : 125 - 137
  • [6] Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
    Yavin, Yshai
    Mansfield, Traci A.
    Ptaszynska, Agata
    Johnsson, Kristina
    Parikh, Shamik
    Johnsson, Eva
    DIABETES THERAPY, 2016, 7 (01) : 125 - 137
  • [7] Effects of SGLT2 inhibitors on the intestinal bacterial flora in Japanese patients with type 2 diabetes mellitus
    Kusunoki, Masataka
    Hisano, Fumiya
    Matsuda, Shin-ichi
    Kusunoki, Akiko
    Wakazono, Naomi
    Tsutsumi, Kazuhiko
    Miyata, Tetsuro
    DRUG RESEARCH, 2023, 73 (07) : 412 - 416
  • [8] Novel therapeutic option in type 2 diabetes patients - practical experience with canagliflozin, SGLT2 inhibitor
    Milczarczyk, Alicja
    Franek, Edward
    Cichocka, Edyta
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2015, 4 (05): : 204 - 209
  • [9] Pilot analysis of the effect of the SGLT2 inhibitor dapagliflozin on blood pressure in patients with type 2 diabetes mellitus: a pooled analysis of placebo controlled trials
    Sjostrom, C. D.
    Sugg, J.
    Tjoen, C.
    Salsali, A.
    Ptaszynska, A.
    Parikh, S.
    EUROPEAN HEART JOURNAL, 2012, 33 : 680 - 680
  • [10] Efficacy and safety of SGLT2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes
    Nomiyama, Takashi
    Tanabe, Makito
    Murase, Kunitaka
    Motonaga, Ryoko
    Yanase, Toshihiko
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S93 - S93
12345